[The effect of treatment with superoxide dismutase and selenium on blood ferritin and transferrin level in patients with hemoblastosis].
The effect of superoxide dismutase (SOD) and selenium on the blood level of ferritin and transferrin in patients with hemoblastosis was studied. Two-month treatment with SOD and selenium had no effect on the level of ferritin but reduced the concentration of malonic dialdehyde (MDA) in the native erythrocytes in patients with chronic lymphoid leukemia practically to that in healthy individuals. In erythrocytes which formed from cells of the leukemic clone (chronic myelocytic leukemia and erythremia) treatment with SOD and selenium reduced the pathologically high level of ferritin, but at the same time increased the concentration of MDA in the erythrocytes. In erythremia in the group with a low level of ferritin SOD and selenium caused no statistically significant increase in its level in blood.
Kumerova
A O
AO
Petukhov
V I
VI
Letse
A G
AG
Silova
A A
AA
Shkesters
A P
AP
D001798:Blood Proteins / Q000187:drug effects / Q000378:metabolism; D004912:Erythrocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D005293:Ferritins / Q000187:drug effects / Q000378:metabolism*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D009391:Nephelometry and Turbidimetry; D011087:Polycythemia Vera / Q000188:drug therapy; D012643:Selenium / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D013482:Superoxide Dismutase / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D014168:Transferrin / Q000187:drug effects / Q000378:metabolism*
D001798:Blood Proteins; D006454:Hemoglobins; D014168:Transferrin; D008315:Malondialdehyde; D005293:Ferritins; D013482:Superoxide Dismutase; D012643:Selenium